According to the most recent analysis by Emergen Research, the market for duchenne muscular dystrophy in the world reached $1.03 billion in 2021 and is projected to grow at a rate of 40.7% over the forecast period. The prevalence of duchenne muscular dystrophy is rising, and there are more clinical trials and studies being conducted in the area of duchenne muscular dystrophy-based treatments, which are key contributors in the market's expansion. Additionally, the market for drugs to treat Duchenne muscular dystrophy has shown tremendous revenue increase in recent years due to the quick development of these drugs in clinical trials.
The report studies the historical data of the Duchenne Muscular Dystrophy market and offers valuable information about the key segments and sub-segments, revenue generation, demand and supply scenario, trends, and other vital aspects. The report offers an accurate forecast estimation of the Duchenne Muscular Dystrophy industry based on the recent technological and research advancements. It also offers valuable data to assist the investors in formulating strategic business investment plans and capitalize on the emerging growth prospects in the Duchenne Muscular Dystrophy market.
The global Duchenne Muscular Dystrophy industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
PTC Therapeutics, Eli Lilly and Company, Sarepta Therapeutics, Bristol-Myers Squibb Company, Nippon Shinyaku, Acceleron Pharma Inc., BioMarin Pharmaceutical, Inc., Pfizer, Ltd., Tahio Pharmaceutical Co. Ltd., and Lexicon Pharmaceuticals, Inc.
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Duchenne Muscular Dystrophy market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Duchenne Muscular Dystrophy market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Duchenne Muscular Dystrophy market.
Market Segmentations of the Duchenne Muscular Dystrophy Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Duchenne Muscular Dystrophy market on the basis of product, application, and region:
Segments Covered in this report are:
Treatment Type Outlook (Revenue, USD Million; 2019-2030)
Corticosteroid therapy
Exon-Skipping Therapy
Mutation Suppression
Gene Therapy
End-Use Outlook (Revenue, USD Million; 2019-2030)
Hospitals & Clinics
Home-Care
Others
Regional Outlook (Revenue, USD Million; 2019-2030)
